Advocacy intelligence hub — real-time data for patient organizations
Boston University — NA
King Fahad Armed Forces Hospital
University of Stellenbosch — NA
University of California, San Francisco — NA
Regeneron Pharmaceuticals — PHASE1
Medical University of Warsaw — NA
Medical University of Warsaw — NA
University of California, Irvine — NA
CARNEXIV: FDA approved
Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
CARNEXIV
Lundbeck LLC
CARNEXIV
(intravenous carbamazepine)Orphan drugLundbeck LLC
Bonaventure Orizu, MD
Inovio Pharmaceuticals
Nina Langeland, MD, PhD
University of Bergen
Richard T Davey, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
📍 BETHESDA, MD
Alexandre Chan, PharmD
UCI
Frank Tanser, PhD
University of Stellenbosch
Raffaele Bugiardini, MD
University of Bologna